Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23554

1.

Clinical decision tools are needed to identify HIV-positive patients at high risk for poor outcomes after initiation of antiretroviral therapy.

McNairy ML, Abrams EJ, Rabkin M, El-Sadr WM.

PLoS Med. 2017 Apr 18;14(4):e1002278. doi: 10.1371/journal.pmed.1002278. eCollection 2017 Apr.

2.

Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors.

Van Hout A, D'huys T, Oeyen M, Schols D, Van Loy T.

PLoS One. 2017 Apr 14;12(4):e0176057. doi: 10.1371/journal.pone.0176057. eCollection 2017.

3.

Improving early identification of HIV-infected neonates with birth PCR testing in a large urban hospital in Johannesburg, South Africa: successes and challenges.

Technau KG, Kuhn L, Coovadia A, Carmona S, Sherman G.

J Int AIDS Soc. 2017 Apr 10;20(1):1-8. doi: 10.7448/IAS.20.01/21436.

PMID:
28406596
4.

Changes in estimated glomerular filtration rate over time in South African HIV-1-infected patients receiving tenofovir: a retrospective cohort study.

De Waal R, Cohen K, Fox MP, Stinson K, Maartens G, Boulle A, Igumbor EU, Davies MA.

J Int AIDS Soc. 2017 Apr 10;20(1):1-8. doi: 10.7448/IAS.20.01/21317.

PMID:
28406595
5.

Lower genetic variability of HIV-1 and antiretroviral drug resistance in pregnant women from the state of Pará, Brazil.

Machado LF, Costa IB, Folha MN, da Luz AL, Vallinoto AC, Ishak R, Ishak MO.

BMC Infect Dis. 2017 Apr 12;17(1):270. doi: 10.1186/s12879-017-2392-y.

6.

Modelling CD4 T Cell Recovery in Hepatitis C and HIV Co-infected Children Receiving Antiretroviral Therapy.

Majekodunmi AO, Thorne C, Malyuta R, Volokha A, Callard RE, Klein NJ, Lewis J; European Paediatric HIV/HCV Co-infection Study group in the European Pregnancy and Paediatric HIV Cohort Collaboration and the Ukraine Paediatric HIV Cohort Study in EuroCoord..

Pediatr Infect Dis J. 2017 May;36(5):e123-e129. doi: 10.1097/INF.0000000000001478.

7.

Community-based strategies to strengthen men's engagement in the HIV care cascade in sub-Saharan Africa.

Sharma M, Barnabas RV, Celum C.

PLoS Med. 2017 Apr 11;14(4):e1002262. doi: 10.1371/journal.pmed.1002262. eCollection 2017 Apr.

8.

Status and methodology of publicly available national HIV care continua and 90-90-90 targets: A systematic review.

Granich R, Gupta S, Hall I, Aberle-Grasse J, Hader S, Mermin J.

PLoS Med. 2017 Apr 4;14(4):e1002253. doi: 10.1371/journal.pmed.1002253. eCollection 2017 Apr. Review.

9.

Chelation Motifs Affecting Metal-dependent Viral Enzymes: <i>N'</i>-acylhydrazone Ligands as Dual Target Inhibitors of HIV-1 Integrase and Reverse Transcriptase Ribonuclease H Domain.

Carcelli M, Rogolino D, Gatti A, Pala N, Corona A, Caredda A, Tramontano E, Pannecouque C, Naesens L, Esposito F.

Front Microbiol. 2017 Mar 20;8:440. doi: 10.3389/fmicb.2017.00440. eCollection 2017.

10.

Repurposing a Bacterial Immune System to Discover Antiviral Targets.

Bieniasz P.

N Engl J Med. 2017 Mar 30;376(13):1290-1291. doi: 10.1056/NEJMcibr1616057. No abstract available.

PMID:
28355517
11.

Validating a self-report measure of HIV viral suppression: an analysis of linked questionnaire and clinical data from the Canadian HIV Women's Sexual and Reproductive Health Cohort Study.

Carter A, de Pokomandy A, Loutfy M, Ding E, Sereda P, Webster K, Nicholson V, Beaver K, Hogg RS, Kaida A; CHIWOS Research Team..

BMC Res Notes. 2017 Mar 24;10(1):138. doi: 10.1186/s13104-017-2453-8.

12.

Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.

Collier D, Iwuji C, Derache A, de Oliveira T, Okesola N, Calmy A, Dabis F, Pillay D, Gupta RK; French National Agency for AIDS and Viral Hepatitis Research (ANRS) 12249 Treatment as Prevention (TasP) Study Group..

Clin Infect Dis. 2017 Apr 15;64(8):1006-1016. doi: 10.1093/cid/cix015.

PMID:
28329393
13.

High Rates of Transmission of Drug-resistant HIV in Aruba Resulting in Reduced Susceptibility to the WHO Recommended First-line Regimen in Nearly Half of Newly Diagnosed HIV-infected Patients.

Hofstra LM, Sánchez Rivas E, Nijhuis M, Bank LEA, Wilkinson E, Kelly K, Mudrikova T, Schuurman R, de Oliveira T, de Kort J, Wensing AMJ.

Clin Infect Dis. 2017 Apr 15;64(8):1092-1097. doi: 10.1093/cid/cix056.

PMID:
28329390
14.

TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.

Wyles D, Saag M, Viani RM, Lalezari J, Adeyemi O, Bhatti L, Khatri A, King JR, Hu YB, Trinh R, Shulman NS, Ruane P.

J Infect Dis. 2017 Feb 15;215(4):599-605. doi: 10.1093/infdis/jiw597.

PMID:
28329334
15.

A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy.

Araínga M, Edagwa B, Mosley RL, Poluektova LY, Gorantla S, Gendelman HE.

Retrovirology. 2017 Mar 9;14(1):17. doi: 10.1186/s12977-017-0344-7.

16.

Novel fused pyrimidine and isoquinoline derivatives as potent HIV-1 NNRTIs: a patent evaluation of WO2016105532A1, WO2016105534A1 and WO2016105564A1.

Kang D, Huo Z, Wu G, Xu J, Zhan P, Liu X.

Expert Opin Ther Pat. 2017 Apr;27(4):383-391. doi: 10.1080/13543776.2017.1303046. Epub 2017 Mar 9. Review.

PMID:
28276283
17.

Dapivirine Vaginal Ring for HIV-1 Prevention.

Winceslaus SJ.

N Engl J Med. 2017 Mar 9;376(10):994-5. doi: 10.1056/NEJMc1616546. No abstract available.

PMID:
28276229
18.

Dapivirine Vaginal Ring for HIV-1 Prevention.

Seidman D, Weber S, Aaron E.

N Engl J Med. 2017 Mar 9;376(10):995. doi: 10.1056/NEJMc1616546. No abstract available.

PMID:
28273024
19.

Dapivirine Vaginal Ring for HIV-1 Prevention.

Baeten JM, Brown ER, Hillier SL.

N Engl J Med. 2017 Mar 9;376(10):995-6. doi: 10.1056/NEJMc1616546. No abstract available.

20.

High levels of virological failure with major genotypic resistance mutations in HIV-1-infected children after 5 years of care according to WHO-recommended 1st-line and 2nd-line antiretroviral regimens in the Central African Republic: A cross-sectional study.

Mossoro-Kpinde CD, Gody JC, Mboumba Bouassa RS, Mbitikon O, Jenabian MA, Robin L, Matta M, Zeitouni K, Longo JD, Costiniuk C, Grésenguet G, Touré Kane NC, Bélec L.

Medicine (Baltimore). 2017 Mar;96(10):e6282. doi: 10.1097/MD.0000000000006282.

Supplemental Content

Loading ...
Support Center